FCGR2A and breast carcinoma: Hence, in this study, we evaluate the presence of FcγRs and FcγR-expressing immune cells in the breast cancer TME, including that of chemotherapy-resistant residual tumors, in which there is a significant unmet need for effective therapies, and baseline tumors from patients who subsequently responded to trastuzumab therapy.